紫杉醇静脉滴注联合顺铂腹腔给药治疗晚期卵巢癌32例疗效及安全性观察

目的探讨紫杉醇静脉滴注联合顺铂腹腔给药治疗晚期卵巢癌的临床疗效及不良反应。方法选取2010年2月至2013年2月医院收治的64例晚期卵巢癌患者,随机分为两组,各32例。观察组患者给予紫杉醇静脉滴注联合顺铂腹腔化疗给药,对照组患者给予2种药物静脉滴注,4个疗程后比较两组患者的临床疗效和不良反应。结果观察组有效率和疾病控制率分别为81.25%和100.00%。明显高于对照组的56.25%和78.12%（P〈0.05）;观察组CA125水平下降有效率为59.38%,明显高于对照组的34.38%（P〈0.05）;两组患者的主要不良反应为骨髓移植、脱发、胃肠道反应、肝功能损害、神经毒性、关节肌肉痛等,观察组不良反应发生率虽低于对照组,但两组间差异无统计学意义。结论紫杉醇静脉滴注联合顺铂腹腔化疗治疗晚期卵巢癌的临床疗效确切。不良反应患者可耐受,是较理想的治疗方法。

Effect and Safety of Intravenous Paclitaxel plus Intraperitoneal Cisplatin Chemotherapy in Treating Advanced Ovarian Carcinoma in 32 Cases

Objective To observe the clinical efficacy and adverse reactions of intravenous paclitaxel plus intraperitoneal cisplatin chemotherapy in treating advanced ovarian carcinoma. Methods 64 patients with advanced ovarian carcinoma admitted to the hospital from February 2010 to February 2013 were randomly divided into the observation group and the control group, 32 cases in each group. The observation group received intravenous the chemotherapy of intravenous paclitaxel plus intraperitoneal cisplatin, while the control group received these two drugs by intravenous drip. The clinical effects and adverse reactions after 4 course of treatment were compared between the two groups. Results The effective rate and the disease control rate in the observation group were 81.25% and 100.00%, while which in the control group were 56.25% and 78.12%, the difference had statistically significant between the two groups（ P 〈 0.05）. The effective rate of the CA125 level decrease in the observation group was 59.38%, which was statistically higher than 34. 38% in the control group（P〈0.05）. The major toxic and side effects were myelosuppression, hair loss, gastrointestinal tract re- actions, liver function impairment, neural toxicity, joint and muscle pain, cardiac anomalies and so on. The adverse reactions of the obser- vation group were less than those of the control group, but no statistical differences between the two groups were found（ P 〉 0. 05）. Conclusion The chemotherapy of intravenous paclitaxel plus intraperitoneal cisplatin has definite effect in treating advanced ovarian cancer and the tolerable toxic and side effects, which is a more ideal treatment method of advanced ovarian cancer.